Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
41.48
-2.67 (-6.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,018,196
Open
42.95
Bid (Size)
41.13 (1)
Ask (Size)
44.97 (1)
Prev. Close
44.15
Today's Range
41.38 - 43.73
52wk Range
6.400 - 44.33
Shares Outstanding
58,310,703
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Chart Of The Day: Dyne Therapeutics - Deeply Discounted
July 10, 2024
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United...
Via
Talk Markets
Performance
YTD
+217.61%
+217.61%
1 Month
+30.48%
+30.48%
3 Month
+67.12%
+67.12%
6 Month
+149.13%
+149.13%
1 Year
+275.38%
+275.38%
More News
Read More
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
June 24, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 13, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
June 12, 2024
Via
Benzinga
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
June 12, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
Via
InvestorPlace
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
May 28, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 21, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Is Dyne Therapeutics Stock Soaring On Monday?
May 20, 2024
Via
Benzinga
Tech Surge Boosts Nasdaq To Record Highs
May 20, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
May 20, 2024
Via
Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
May 20, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 20, 2024
Via
InvestorPlace
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
May 20, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
May 19, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
May 02, 2024
Via
InvestorPlace
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 27, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Via
Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.